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Introduction: Mammographic density (MD), after adjustment for a women’s age and body mass index, is a strong
and independent risk factor for breast cancer (BC). Although the BC risk attributable to increased MD is significant
in healthy women, the biological basis of high mammographic density (HMD) causation and how it raises BC risk
remain elusive. We assessed the histological and immunohistochemical differences between matched HMD and
low mammographic density (LMD) breast tissues from healthy women to define which cell features may mediate
the increased MD and MD-associated BC risk.
Methods: Tissues were obtained between 2008 and 2013 from 41 women undergoing prophylactic mastectomy
because of their high BC risk profile. Tissue slices resected from the mastectomy specimens were X-rayed, then
HMD and LMD regions were dissected based on radiological appearance. The histological composition, aromatase
immunoreactivity, hormone receptor status and proliferation status were assessed, as were collagen amount and
orientation, epithelial subsets and immune cell status.
Results: HMD tissue had a significantly greater proportion of stroma, collagen and epithelium, as well as less fat, than
LMD tissue did. Second harmonic generation imaging demonstrated more organised stromal collagen in HMD tissues
than in LMD tissues. There was significantly more aromatase immunoreactivity in both the stromal and glandular
regions of HMD tissues than in those regions of LMD tissues, although no significant differences in levels of oestrogen
receptor, progesterone receptor or Ki-67 expression were detected. The number of macrophages within the epithelium
or stroma did not change; however, HMD stroma exhibited less CD206+ alternatively activated macrophages. Epithelial
cell maturation was not altered in HMD samples, and no evidence of epithelial–mesenchymal transition was seen;
however, there was a significant increase in vimentin+/CD45+ immune cells within the epithelial layer in HMD tissues.
Conclusions: We confirmed increased proportions of stroma and epithelium, increased aromatase activity and no
changes in hormone receptor or Ki-67 marker status in HMD tissue. The HMD region showed increased collagen
deposition and organisation as well as decreased alternatively activated macrophages in the stroma. The HMD
epithelium may be a site for local inflammation, as we observed a significant increase in CD45+/vimentin+
immune cells in this area.* Correspondence: e2.thompson@qut.edu.au
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Important risk factors for breast cancer (BC) are increas-
ing age, genetic mutations, family history or personal
history of BC and mammographic density (MD), which
refers to the extent of opaque appearance on a mammo-
gram [1]. The radiological appearance of the breast differs
among women owing to varying proportions of radio-
dense fibroglandular tissue that appears white and radio-
lucent adipose tissue that appears dark [2]. Women with
breasts that have 75 % or greater mammographically
dense tissue are four to six times more likely to develop
BC than are women with breasts that have 10 % or less
mammographically dense tissue, and this risk has been
shown to persist over 10 years of follow-up [3].
High mammographic density (HMD) is not uncom-
mon in the community. In a study of 1353 women in
America, researchers found that 42 % of the 40- to 59-
year-old age group and 25 % of the 60- to 79-year old
age group have breasts that are at least 50 % mammo-
graphically dense [4]. Although 55 % to 65 % of BRCA1
mutation carriers develop BC by the age of 70, these
cases are estimated to account for just 2 % to 5 % of all
BCs [5, 6]. By contrast, the prevalence of HMD suggests
that as many as 30 % of BC cases could be attributable
to elevated MD [7], should the MD–BC risk association
be causal [8]. The link between high MD and BC risk is
now in the public domain. Advocacy groups such as Are
You Dense? [9] have provided education to the public
and helped advocate changes in public policy. As of
December 2014, Breast Density Inform laws, which call
for mandatory reporting of MD status, had been intro-
duced in 20 states across the United States [10]. As the
biological basis of MD is not understood, viable pre-
ventative and/or therapeutic targets aimed at reducing
MD-associated BC risk have yet to be developed.
To date, various studies have examined the histological
and molecular differences of HMD and low mammo-
graphic density (LMD) breast tissues. HMD tissue has
been shown to be composed of greater areas of stroma,
but less fat, than LMD tissue; however, findings on
whether HMD area contains higher amounts of epithe-
lium are conflicting [11, 12], and epithelial cell prolifera-
tion appeared to be increased in some studies, but not
in others [11, 13]. The proportion of basal and luminal
cell layers within the epithelium has never been assessed,
and change in this proportion is one of the first steps in
tumorigenesis [14, 15]. The composition of the stroma
has been examined in a few studies [12, 16, 17], which
have shown that the degree of collagen deposition is
increased in HMD tissue [18–20]; however, collagen
organisation has not been assessed. The abundance and
phenotype of immune cells, now an acknowledged com-
ponent of the tumour microenvironment [21], have also
never been assessed in HMD tissue.In an attempt to define the tissue components respon-
sible for the increased MD, we analysed the epithelial,
stromal and adipose compositions and further investi-
gated the stromal and epithelial compartments. We
assessed differentiation, proliferation, hormone receptor
and aromatase expression in the epithelium; collagen
content and organisation; and immune cell status. In an
effort to assess the possible role of epithelial–mesenchy-
mal transition (EMT), which has been implicated in
many aspects of malignancy [22, 23], we included
vimentin in our analysis of epithelial cells.Methods
The study population
This study was approved by the Peter MacCallum Human
Research Ethics Committee (number 08/21) and St.
Vincent’s Hospital Animal Ethics Committee (number 049/
09). It was conducted in accordance with the Australian
National Statement on Ethical Conduct in Human Re-
search [24]. Between 2008 and 2013, 48 women undergoing
prophylactic mastectomy for BC prevention at St. Vincent’s
Hospital were consented through the Victorian Cancer
Biobank (VCB 10010) to participate in this study. These
women had either a confirmed BRCA1/2 carrier status, a
past history of BC in the other breast or a family history of
two or more first- or second-degree relatives with BC who
were diagnosed before the age of 50 years. Women were
excluded from this study if there were any clinical suspi-
cions of ductal carcinoma in situ (DCIS) or microcalcifica-
tions seen on radiological investigations.Tissue accrual and selection of high and low
mammographically dense regions
Resected breast tissue was transferred immediately to
the pathology department upon completion of mastec-
tomy, where pathologists resected slices of breast tissue
using a sterile technique. X-rays of those slices were
taken by a breast radiographer using uniform radio-
logical parameters and were assessed against a calibra-
tion ruler for selection of HMD and LMD regions. The
tissue slice was transferred to a biosafety level 2 hood,
where areas that appeared white on X-rays were selected
and removed using sterile blades and defined as HMD
regions, and areas that appeared black were similarly se-
lected, removed and classified as LMD regions. When
the tissue slice mammogram appeared homogeneously
grey or lacked black-white differential, the patient was
excluded from the study. This method was detailed in
our previous work [12, 25].
The tissue samples were then fixed in 10 % neutral
buffered formalin, processed through alcohol, embedded
in paraffin blocks and then sectioned at 5-μm thickness
for histological analyses.
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Conventional haematoxylin and eosin (H&E) staining
was performed on paired HMD and LMD tissue sections
cut from the blocks as described above. Stained entire
tissue sections were photographed using an Aperio
ScanScope XT digital microscope (Leica Biosystems,
Buffalo Grove, IL, USA) at ×20 magnification to gener-
ate high-resolution images, which were then exported
into JMicroVision image analysis software (v.1.2.7;
University of Geneva, Geneva, Switzerland). The whole
tissue image was used to assess tissue composition,
which was achieved by manually demarcating the entire
tissue area as well as individual areas of dense connect-
ive tissue and epithelium and applying thresholding
masks to stromal and epithelial areas separately to calcu-
late the percentage of these components relative to the
whole tissue section. This method has been described in
detail previously [25].
Mammographic density tissue index
To assess whether a semiquantitative histological assess-
ment of MD could help select HMD and LMD speci-
mens where radiological guidance may be unavailable,
an MD tissue index was employed to examine any po-
tential difference between HMD and LMD tissues that
were sampled, based on their X-ray appearance, in this
study. Two examiners were independently blinded to all
details of the specimen and, by looking at the whole tis-
sue section, assigned the tissue samples to one of the fol-
lowing five categories: (1) 0 to 10 % of the tissue section
was stroma and/or epithelium; (2) 11 % to 25 % of the
tissue section was stroma and/or epithelium; (3) 26 % to
50 % of the tissue section was stroma and/or epithelium;
(4) 51 % to 75 % of the tissue section was stroma and/or
epithelium; or (5) more than 75 % of the tissue section
was stroma and/or epithelium.
Immunohistochemical Masson’s trichrome blue staining
A total of 15 pairs of HMD and LMD tissue samples were
selected, based on the presence of epithelium on H&E-
stained images, to represent the characteristics of the
mammary specimens. They were used for all further ana-
lyses. Masson’s trichrome blue (MTB) staining was used
to demonstrate the quantity of fibrillar collagens in HMD
and LMD tissue sections, and Ki-67 antibody (clone MIB-
1, catalogue number M7240; Dako, Carpinteria, CA, USA)
was used for assessing and comparing proliferation status.
Oestrogen receptor (ER, clone SP1, catalogue number
790-2223; Ventana Medical Systems, Tucson, AZ, USA)
and progesterone receptor (PR, clone SP1, catalogue num-
ber 790-2223; Ventana Medical Systems) status were also
analysed immunohistochemically. Staining was performed
as described previously [25]. JMicroVision image analysis
software v.1.2.7 was used to quantify nuclear staining ofER, PR and Ki-67. Glandular areas were manually selected
as polygons, and positive and negative staining was
assigned as class 1 and 2, respectively, with different key-
strokes. The point-counting system was used to randomly
count approximately 300 points for calculation of the per-
centage of positive staining in total glandular areas per
whole tissue section. Similarly to H&E-stained tissue sec-
tions, MTB-stained tissue slides were scanned using an
Aperio digital microscope, and high-resolution images
were exported into JMicroVision for quantification of col-
lagen content by thresholding the blue-stained collagen
and calculating the percentage of collagen per whole tissue
section.Aromatase immunostaining
Aromatase immunostaining was performed as previously
described [26]. In brief, tissue sections were incubated in
10 % horse serum in CAS-Block reagent (Invitrogen/Life
Technologies, Carlsbad, CA, USA) for 30 minutes. Pre-
viously characterized aromatase mouse monoclonal pri-
mary antibody 677 (1:750 dilution from 2.6 mg/ml stock
in 0.5 % bovine serum albumin/phosphate-buffered sa-
line (PBS) [27]) was added to the slides and incubated
overnight at 4 °C. After the slides were washed in PBS,
biotinylated universal secondary antibody (1:200 dilu-
tion, VECTASTAIN Elite ABC Kit (Mouse IgG); Vector
Laboratories, Burlingame, CA, USA) was applied for 30
minutes and then incubated with VECTASTAIN ABC-
HP reagent for 30 minutes. 3,3-Diaminobenzidine
tetrahydrochloride (Sigma-Aldrich, St. Louis, MO, USA)
was added until the desired cytoplasmic brown stain in-
tensity developed, and the reaction was then stopped
with distilled water. For scoring, we used four high-
magnification (×40) images of each section of HMD and
LMD obtained from each of the 15 women. Sections
were blinded for assessment, and two independent ex-
aminers determined the levels of stromal and epithelial
aromatase expression as proportions of total epithelial
and stromal cells.Second harmonic generation imaging
Unstained paraffin sections (15 μm) of HMD and LMD
tissue obtained from eight randomly selected women
were used for second harmonic generation (SHG) im-
aging. Imaging was performed on a Leica SP8 inverted
multiphoton microscope (Leica Microsystems) with a
long working distance, ×25 magnification, 0.95 numer-
ical aperture water objective. The multiphoton laser
(Chameleon Vision II; Coherent, Santa Clara, CA, USA)
was operated at 80 MHz and tuned to an excitation
wavelength of 960 nm. SHG signals were collected on a
nondescanned external hybrid detector located at the
back focal plane of the objective. A 480/40-nm emission
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sizes were generated for each section.
Grey-level co-occurrence matrix analysis
Grey-level co-occurrence matrix (GLCM) analysis was
performed to assess stromal collagen fibre structure and
organisation in HMD and LMD tissue samples. This
method allows assessment of the level of structural col-
lagen organisation, as previously described [28, 29].
GLCM was performed using a macro in ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
First, the user selected a directory containing the colla-
gen stack images. A maximum projection image was
then produced and duplicated, from which the user se-
lected three 74 × 74–μm regions of interest (ROIs). The
image data in each ROI was passed to the GLCM plugin
(UMB GLCM features [30]), which was modified to
allow the testing of numerous directions and distances
of comparison. The output of the plugin for each ROI
was 100 rows of the 5 texture parameters (contrast, uni-
formity, correlation, homogeneity and entropy) over
each of 4 directions, so, in total, 2000 parameter values
were obtained. These were saved as a text data file for
each ROI. Once all the images in the directory were ana-
lysed, the data files were processed using a MATLAB
(MathWorks, Chatswood, Australia) script that outputs
the mean (with SEM) value of each texture parameter
for each image. The results of the GLCM correlation
where then imported into GraphPad, Prism software
(GraphPad Software, La Jolla, CA, USA), where a double
exponential decay model was fitted to the data and the
weighted mean decay distance for each sample was
calculated.
Macrophage staining
To assess the effect of MD on the abundance, location
and phenotype of macrophages, the 15 paired LMD and
HMD tissue sections were stained with a pan-macrophage
marker CD68 (clone PG-M1, catalogue number M0876;
Dako), as well as CD206, also known as macrophage man-
nose receptor 1, which is a marker of alternative macro-
phage activation involved in resolution of inflammation
(CD206 monoclonal antibody, clone 685645; R&D Sys-
tems, Minneapolis, MN, USA). The stained sections were
imaged using a NanoZoomer digital slide scanner
(Hamamatsu Photonics, Hamamatsu, Japan). Epithelial
cell– and stromal cell–associated macrophages were
manually counted and quantified per square millimetre of
tissue in three randomly selected glandular and stromal
areas within each tissue sample.
Immunofluorescence staining for lineage markers
Cytokeratin-19 [CK-19, Pierce A53-B/A2.26 (Ks19.1);
Thermo Scientific, Waltham, MA, USA], CK-14(CBL197; EMD Millipore, Bayswater, Australia) and
vimentin (clone V9, catalogue number M0725; Dako)
triple immunofluorescence (IF) staining was performed
on the selected 15 pairs of HMD and LMD tissues. CK-
19 and CK-14 were used to delineate luminal epithelial
cells and basal epithelial cells, respectively. To enhance
the clarity of histological composition, vimentin was also
used to illustrate the stromal component in both HMD
and LMD groups, as well as any evidence of EMT. Five
images of glandular areas were taken randomly for each
specimen using a Nikon C2si confocal microscope
(Nikon Instruments, Melville, NY, USA). Point counting
using JMicroVision, similarly to that employed for ER, PR
and Ki-67 quantitative analyses as mentioned above, was
used to assess the proportions of basal epithelial cells
stained for CK-14, luminal epithelial cells stained for CK-
19, and mesenchymal cells stained for vimentin. Triple
staining was performed to examine the level of immune
cell infiltration in these tissues, pan-macrophage marker
CD68 (clone PG-M1, catalogue number M0876; Dako),
pan-CK (clone Oscar, catalogue number MON3267;
MONOSAN, Uden, the Netherlands) and mesenchymal
marker vimentin (clone V9; Dako). Furthermore, pan-
inflammatory marker CD45 (clones 2B11 and pd7/26,
catalogue number M0701; Dako) and mesenchymal
marker vimentin (clone LN-6, catalogue number V2258;
Sigma-Aldrich) double IF staining was performed.
Statistical analysis
HMD and LMD tissue biopsies from the same breast of
the same woman were analysed in a pairwise manner,
which overcame potential confounding factors such as
age, body mass index (BMI), menstrual cycle and meta-
bolic activity. Normality was determined using the
D’Agostino-Pearson omnibus normality test. Wilcoxon
matched-pairs signed-rank test was used for nonpara-
metric data to determine the percentage composition of
epithelial, stromal and adipose tissues within each sam-
ple for H&E-stained tissue; of collagen for MTB-stained
tissue; for macrophage staining; and of basal, luminal
and mesenchymal cells in CK- and vimentin-stained tis-
sues. For parametric data, a paired t test was used to com-
pare the percentage of ER and PR staining and of Ki-67
expression between HMD and LMD tissues. The P value
was required to be less than 0.05 to achieve statistical sig-
nificance. All tests were performed in GraphPad, Prism
software.
Results
The study cohort
A total of 48 high-risk women were included in this
study; however, of these, 4 women had suspicious DCIS
based on specimen radiographs, and 3 women had tissue
samples with a homogeneous radiological appearance.
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mens were sent for standard pathological processing,
leaving a final cohort of 41 women eligible for this
study.
The participant characteristics are detailed in Table 1.
All candidates were Caucasian, and their mean age was
43 years (range 31-59 years). They all underwent
prophylactic mastectomy owing to a high BC risk pro-
file. Of the 41 participants, 28 were premenopausal and
37 had borne children. Their MD was rated according to
the BI-RADS classification scheme. Their final histo-
pathology reports regarding their mastectomy tissue
confirmed that the breast was free of DCIS or cancer. Of
the 15 women selected for further analysis, 14 were pre-
menopausal and 13 had borne children. Hence, our
overall results represented a premenopausal and parous
cohort.
Histological composition of high and low mammographic
density tissue
Quantitative analysis of 41 paired specimens found that
HMD tissue had 31.57 % more stroma, 4.82 % more
glandular area and 36.39 % less fat than LMD tissue in
terms of mean percentage, and each of those differences
was statistically significant (P < 0.0001) (Fig. 1). If a
semiquantitative histological MD tissue index as defined
in the Methods section was used. This index wasTable 1 Demographic characteristics of study participants
Selected characteristics Number or mean
Age at surgery Mean 43 yr (range 31–59 yr)
BI-RADS category
4 11
3 16
2 10
1 4
Risk factors
BRCA−, strong family history 9
BRCA1+ 15
BRCA2+ 13
Past history of BC or DCIS 24
Menopausal status
Premenopausal 28
Perimenopausal 5
Postmenopausal 8
Parity
Parous 37
Nulliparous 4
BI-RADS score 1: predominantly fat, 2: scattered fibroglandular densities, 3:
heterogeneously dense, 4: extremely dense.
Abbreviations: BC breast cancer, BI-RADS Breast Imaging-Reporting and Data
System, DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma.developed to assess MD in samples where mammograms
are not readily available, and the HMD samples classified
as such by X-ray analysis were also scored as HMD in
the MD tissue index (P < 0.0001) (see Additional file 1).
We further divided the data according to parity status
(parous vs. nulliparous) and menopausal status (pre-,
peri- or postmenopausal). Separate quantitative analyses
by parity and menopausal status showed that the differ-
ences of epithelium, stroma and fat composition be-
tween HMD and LMD tissue were still significant in 37
parous women and in 28 premenopausal women. In a
parous and premenopausal subset of 25 women, HMD
tissue exhibited the same patterns of significantly in-
creased epithelium, stroma and reduced fat compared
with LMD tissue (see Additional files 2 and 3).
Masson’s trichrome blue staining
Consistent with the stromal differentials between HMD
and LMD tissues that were evident on H&E staining, MTB
staining showed a significantly higher amount of fibrillar
collagen in HMD tissue than in LMD tissue (P < 0.0001).
In both groups, collagen aligned circumferentially around
glandular epithelium, although it was more densely
packed in HMD sections than in LMD sections, as shown
in Fig. 2.
Second harmonic generation imaging and grey-level co-
occurrence matrix analysis of stromal collagen
On eight matched, randomly selected HMD and LMD
samples, we assessed the collagen structure using SHG
imaging coupled with GLCM texture analysis. The
GLCM analysis shows the correlation of the intensity of
the SHG signal across the analysed region. Samples with
a slower decay have a more organized, uniform collagen
structure than samples with a faster decay. The mean
decay parameter (slope) in a biexponential fit model of
correlation decay curve was calculated and plotted for
each sample (matched HMD and LMD samples, indi-
cated on the x-axis). The ratio of the mean decay of
HMD to LMD was calculated to determine whether
HMD samples contained a higher collagen organization
than LMD samples. A ratio above 1 indicates that HMD
samples had a higher collagen organization than LMD
samples. We found that 75 % of HMD patient samples
showed a higher mean decay than LMD patient samples
(Fig. 3).
Commonly used breast cancer markers in high and low
mammographic density tissue
ER, PR and Ki-67 staining occurred predominantly in
the epithelial areas, with sparse staining observed in the
stromal cells, as illustrated in Fig. 4. The percentage of
ER and PR nuclear staining in glandular area per whole
tissue section was similar between HMD and LMD
Fig. 1 Haematoxylin and eosin–stained high mammographic density (HMD) and low mammographic density (LMD) tissue sections. (a)
Representative photomicrograph of tissue specimen resected from an HMD region. (b) Representative photomicrograph of tissue specimen
resected from an LMD region of the same healthy breast shown in (A). (c) Selected area from HMD tissue shown in (A) at ×10 original
magnification. (d) Selected area from HMD tissue shown in (B) at ×10 original magnification. (e) Scatterplots of percentages of stroma, epithelium
and fat of HMD and LMD within-individual tissue (N = 41 women)
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the glandular area confirmed that there were no statisti-
cally significant differences. Ki-67-positive expression as
a marker for proliferation was overall less than 10 % of
stained nuclei of all epithelial cells per tissue section in
both HMD and LMD tissues. There was a nonsignificant
trend for HMD tissue to have a mean 2 % higher Ki-67
expression than LMD tissue.
Cells with positive cytoplasmic aromatase staining
were counted. The percentages of aromatase-positiveepithelial and stromal cells were significantly increased
in HMD compared with LMD tissue (Fig. 5). Qualita-
tively, aromatase staining was observed to be more
prevalent in the luminal compared with basal epithelial
layer of HMD tissues (Fig. 5a, c).
Macrophage staining
We assessed the paired HMD and LMD tissue sections
for macrophage abundance, location and phenotype
using CD68 and CD206 immunohistochemistry, as
Fig. 2 Masson’s trichrome blue staining of high mammographic density (HMD) and low mammographic density (LMD) tissue samples.
Photomicrographs show representative staining patterns of HMD tissue (a) and LMD tissue (b) of the 15 women assessed. (c) Scatterplot shows
the percentages of blue-stained collagen of HMD and LMD tissue
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(CD68+) was not significantly altered in either the epi-
thelial or stromal compartments. However, within the
HMD stromal regions, there was a significant decrease
in the number of CD206+ alternatively activated macro-
phages (P < 0.01).
Triple immunofluorescence staining for epithelial
maturation and epithelial–mesenchymal transition
There was no significant difference in the proportions of
basal (CK-14+) or luminal (CK-19+) epithelial cells be-
tween HMD and LMD specimens (Fig. 7). No vimentin+
and CK+ double-positive cells were seen in either HMD
or LMD regions, ruling out any overt involvement of
EMT. However, we observed a small minority of cells
within the epithelium (not limited to the basal layer) that
stained positive for vimentin and were negative for both
CK-19 and CK-14 (Fig. 7). Using the same point-
counting method, we found that the percentage of
intraepithelial, vimentin-positive, cytokeratin-negative
(VPCKN) cells was significantly increased in the HMD
group compared with LMD. We further stained the
specimens for pan-CK, CD68 and vimentin to determine
if these VPCKN cells were macrophages. Whilst CD68+
cells were abundant in the epithelium (as well as thestroma), only 25 % to 50 % of the VPCKN cells were
CD68+ (data not shown). To assess if they were immune
cells, CD45 and vimentin double staining was used. All
of the VPCKN cells within the epithelial regions were
immune cells, as they costained with the pan-immune
cell marker CD45 (Fig. 8). As expected, immune cells
were also present throughout the stromal regions.
Discussion
Stromal and epithelial compartments increased in high
mammographic density tissue
Adjusted for age and BMI, MD has consistently been
shown to be a strong and independent risk factor for BC
[31, 32]. Independent of its potential masking effect on
tumours in a mammogram [1, 7, 33, 34], DCIS lesions
were found to occur preferentially in HMD areas in a
retrospective study where mammograms at BC diagnosis
were compared with the most recent previous mammo-
grams [35]. BCs that arise within HMD areas have also
been shown in many studies to consist of features that
suggest poor prognosis, such as high histological grade
and lymphovascular invasion, compared with tumours
that arise from LMD areas [27, 36–40].
The biological basis of MD has been investigated by
various studies in the past decade, most of which were
Fig. 3 Second harmonic generation (SHG) analysis of collagen. (a) Collagen was imaged using an SHG technique. White squares indicate analysed regions.
Scale bar indicates 100 μm. (b) Grey-level co-occurrence matrix (GLCM) analysis shows the correlation of the intensity of the SHG signal across the analysed
region. Samples with a slower decay have a denser collagen structure than samples with a faster decay. For each sample, three regions were imaged.
Within each region, three areas were selected for analysis (total N = 9). Mean parameter values are shown as symbols. Dashed lines represent the nonlinear
biexponential fit to each data set. Error bars indicate SEM. (c) The mean decay parameter (slope) in a biexponential fit model of correlation decay curve was
calculated and plotted for each sample. (d) The ratio of the mean decay of high mammographic density (HMD) to low mammographic density (LMD) was
calculated to determine whether HMD samples contained a higher collagen organisation than LMD samples. A ratio above 1 indicates that HMD samples
had a higher collagen organisation than LMD samples. Seventy-five percent of HMD samples showed a higher mean decay than LMD samples. Horizontal
bar indicates the mean
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of 236 women who had normal breast tissue, Li and col-
leagues, in their autopsy study of accidental deaths,found significantly increased amounts of epithelial tissue
in HMD breast tissue [44]. Hawes et al. examined the
histology of 12 healthy premenopausal women and
Fig. 4 Oestrogen receptor (ER), progesterone receptor (PR) and Ki-67 staining of high mammographic density (HMD) and low mammographic
density (LMD) tissue samples. Representative photomicrographs show ER, PR and Ki-67 brown nuclear staining in selected HMD and LMD regions
of the 15 women. The percentages of positive nuclear staining in glandular areas per whole tissue section were point-counted using JMicroVision,
and the results were analysed using paired t tests
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ated with HMD, but they did not find any difference in
proliferation using Ki-67 staining [13]. This result is con-
sistent with other published data regarding cohorts of 66
women [45] and 59 women [11] of mixed menopausal sta-
tus. However, we previously examined breast tissue in
HMD and LMD regions of the same breast collected using
an image-guided technique, and we did not observe a sig-
nificant difference in the amount of epithelium between
the two MD groups [12]. In this follow-up study of an ex-
tended cohort of such paired samples, we observed a
small but significant increase in epithelial content of
HMD compared with LMD regions in 41 women.
Whereas increased MD may be a partial consequence
of increased epithelium, there was no elevated level ofcellular proliferation, as demonstrated by the Ki-67
staining. In a small case–control study on postmeno-
pausal women who received hormone therapy (HT) (28
receiving HT vs. 28 not receiving HT at the time of BC
diagnosis), researchers found that HMD correlated with
increased Ki-67 expression in ducts and lobules for both
groups, although their data appear to be the only pub-
lished data supporting a positive relationship between
HMD and Ki-67, a result that may be mediated by the
use of hormone therapy in those postmenopausal pa-
tients [46]. By contrast, Ghosh et al. did not observe a
difference in Ki-67 expression when they analysed the
core biopsies of dense and nondense regions of the same
breast in a cohort of 59 healthy women who were either
pre- or postmenopausal [11], which is in keeping with
Fig. 5 Aromatase analysis in high mammographic density (HMD) and low mammographic density (LMD) tissue samples. Cytoplasmic aromatase
immunoreactivity appeared punctate in both epithelial and stromal components of paired HMD and LMD specimens (n = 15 women) (a-d).
Percentages of positive aromatase expression were calculated by manually counting the positively stained cells (brown cytoplasm) and total
number of cells in glandular areas and stroma, respectively (e). Black arrows: positive epithelial cell staining; blue arrows: negative epithelial
staining; black arrowheads: positive stromal cell staining; blue arrowheads: negative stromal cell staining
Huo et al. Breast Cancer Research  (2015) 17:79 Page 10 of 20our findings in such a mixed cohort. In addition, among
344 women at high risk of developing BC, MD did not
show any correlation with Ki-67 activity in a study in
which investigators used tissues obtained by random
periareolar fine-needle aspiration [47]. The assessment
of cell proliferation can be challenging, as it is influenced
by many factors, such as the menstrual cycle, hormone
therapy and parity status. A strength of our study lies in
the paired within-individual assessment, which elimi-
nated these potential confounders. In regard to MD-
associated studies on cancerous mammary tissue, a large
case-only study involving 1975 patients with BC found
no significant difference in the percentage MD between
women who had high or low Ki-67 values in their BCs[48]. Also, in a case–control study of 279 patients with
BC and 159 controls, MD was not associated with sig-
nificantly increased proliferation markers in breast tissue
[49]. The null association between MD and Ki-67
suggests that HMD may increase BC risk through a
mechanism that is separate from increased cellular
proliferation.
Increased stroma is the leading contributing factor for
HMD; thus, it is not surprising that there have been
studies showing that changes in the stromal composition
alone lad to epithelial cancers [20, 50–52]. The breast
stroma is composed of extracellular matrix (ECM),
which not only provides an ultrastructure to support cel-
lular growth but also contributes to cell adhesion,
Fig. 6 (See legend on next page.)
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Fig. 6 Macrophage staining. Macrophage abundance in low mammographic density (LMD) (a, c) and high mammographic density (HMD) (b, d)
paired samples (n = 15) stained with pan-macrophage marker CD68 (A, B) and the C-type lectin receptor macrophage mannose receptor 1 (c, d).
Epithelial cell–associated (arrows) and stromal cell–associated (arrowheads) macrophages were quantified per square millimetre of tissue in three
randomly selected glandular and stromal areas within each tissue sample, and abundance was compared between LMD and HMD paired samples
using the nonparametric Wilcoxon test for epithelium and the paired t test for stroma (data passed the D’Agostino-Pearson omnibus normality
test) (*P < 0.05). Percentage changes in abundance of epithelial and stromal cell–associated CD68 (e) and CD206 (f) in HMD tissue compared with
the LMD paired sample are shown
Huo et al. Breast Cancer Research  (2015) 17:79 Page 12 of 20migration, differentiation and maintenance [19, 53–56].
In addition, ECM was shown to participate in tumori-
genesis and progression of BC through cell surface re-
ceptors such as integrins and growth factors [57–59].
We recently suggested [32] that further analysis of the
collagen content and orientation may shed light on
HMD-associated BC risk, as studies of collagen align-
ment in rats showed that parous rats, which have re-
duced BC incidence, had less linearized collagen than
nulliparous rats [60]. The MTB staining showed that the
increased stromal area (and concurrently decreased adi-
pose tissue) was also associated with an increase in
collagen-rich tissue. The densely packed collagens in
HMD tissue play a key role in stromal stiffness. This
possibility has been supported by various investigations
of stromal ECM, proteoglycan expression and collagen
content in mammary tissue [17, 18, 20, 52, 61–63]. In
those studies, researchers found that HMD was charac-
terised by greater ECM stiffness, increased expression of
lumican and decorin and increased amounts of collagen.
In addition, Conklin and colleagues found that tumour-
associated collagen signature-3 (TACS-3), a collagen
alignment marker, was positively associated with expres-
sion of stromal syndecan 1, a receptor for several ECM
proteins, including collagen. Furthermore, TACS-3 also
correlated with poor disease-free survival in 196 pa-
tients, suggesting that, in addition to collagen content,
the architecture and collagen alignment may be key in
tumorigenesis and invasiveness [64]. We assessed the
collagen organisation using GLCM analysis of SHG im-
ages and found that HMD tissue samples have a higher
organisation than LMD tissue samples. This is consistent
with the work of Provenzano et al. showing that breast
tumour cells often localize near dense collagen or
promote a desmoplastic response [20]. Using Wnt-1
tumour-bearing mice, they showed the presence of in-
creased collagen in areas of hyperplasia before the devel-
opment of palpable tumours [41].
Fat as a breast tissue fraction often is not considered
to play an active role in MD-associated BC risk. How-
ever, Lokate and colleagues found, in a nested case–con-
trol study (358 cases and 859 controls; postmenopausal
women), that local breast fat increased BC risk inde-
pendently of BMI. They also noted that the relationship
with BC is stronger for HMD than for LMD areas, withthe final risk being dependent on the breast composition
[65]. Pettersson et al., in a larger case–control study
[464 cases and 998 controls (premenopausal women)
and 960 cases and 1662 controls (postmenopausal
women)], found that nondense breast area was associ-
ated with decreased BC risk among both groups of
women, and they proposed that local adipose tissue in
the breast may have a protective role against BC [66].
Adipose tissue is known to contain active endocrine cells
that may contribute to perturbations in the breast
microenvironment [67, 68]. For example, oestrogen pro-
duced by fat through conversion of androgens by aroma-
tase has been shown to increase BC risk [69–71].
Adipokines, such as leptin, which are secreted by fat
tissue, also contribute to the development of BC by
stimulating oestrogen biosynthesis and BC cell growth
[72–74]. Although increased adipose tissue overall in the
form of a higher BMI may lead to raised circulating and/
or local levels of oestrogen and subsequent BC risk, fatty
breast tissue per se may reduce BC risk by reducing the
chance of promalignancy interactions between epithelial
cells and the stroma.
The difference in histological composition assessed by
using an MD tissue index correlated with results that
were analysed using JMicroVision for our 41 paired
specimens (see Additional file 1). Hence, where mam-
mograms or X-rays are not available, an MD tissue index
could be a valuable substitute tool to guide the selection
of HMD and LMD breast tissue for future studies.
High mammographic density tissue has increased
aromatase but no changes in hormone receptor
expression
With regard to hormonal modulation of MD, increased
MD can be observed during the luteal phase of the men-
strual cycle, correlating with a woman’s increased serum
levels of circulating endogenous oestradiol and proges-
terone. MD then decreases during the menstrual phase
and plateaus during the follicular phase, despite high
oestradiol levels in that period. Thus, it is likely that
oestradiol and progesterone synergistically cause a tran-
sient rise in MD in the luteal phase [4]. We showed that
MD of human breast tissue in our xenograft murine en-
gineering chambers was influenced by the murine peri-
partum states as well as by tamoxifen treatment of the
Fig. 7 (See legend on next page.)
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Fig. 7 Cytokeratin (CK)-19, CK-14 and vimentin triple immunofluorescence staining. High mammographic density (HMD) (a) and low mammographic
density (LMD) (b) tissue samples were stained with 4′,6-diamidino-2-phenylindole (a1 and b1), CK-14 (a2 and b2) CK-19 (a3 and b3) and vimentin (a4 and
b4) and assessed as composite images (a5 and b5). Arrows indicate cells inside the epithelial layer that stained negative for CK-19 or CK-14, but positive for
vimentin. (c) Using the point-counting method, the percentages of CK-14 basal epithelial cells and CK-19 luminal epithelial cells were determined, as were
the number of vimentin-expressing CK− cells per whole glandular area of the tissue sections. The results for HMD and LMD paired samples were analysed
using the nonparametric Wilcoxon matched-pairs signed-rank test. VPCKN vimentin-positive, cytokeratin-negative. Scale bar = 10 μm
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NOD SCID mice [75, 76]. Our unique within-individual
paired analyses eliminated confounders such as different
stages of the menstrual cycle or menopausal status
among women; however, we did not observe any signifi-
cant difference in the percentage expression of ER and
PR between HMD and LMD tissue within the same indi-
vidual. This is consistent with Ghosh and colleagues’
finding that the relative expression of ER and PR was
similar in dense and nondense tissue of 24 women [11].
Data derived from published epidemiological studies also
showed that, although MD was more strongly associated
with ER-positive than ER-negative BC for women under
the age of 55, HMD is strongly associated with all BC
subtypes [77, 78]. Although in the majority of previousFig. 8 The vimentin+ cells in the epithelial layer are immune cells (CD45+).
samples with 4′,6-diamidino-2-phenylindole (a), vimentin (b) and pan-CD45
(d). (e-g) High-power images of the selected region in (D)studies researchers have reported a null association be-
tween MD and ER or PR status, Ding et al. found that
MD was a stronger risk factor for ER-positive BC than
for ER-negative BC in a group of 370 BC cases with
1904 age-matched controls [36]. Overall, this area re-
mains a controversial topic, and the mechanisms behind
these conflicting findings are poorly understood.
Aromatase is the key driver for local oestrogen
production within the breast after menopause. It is
expressed by the adipose stromal cells and encoded by the
CYP19A1 gene [79, 80]. Aromatase transfection stimulates
BC cell growth in vitro, perhaps via increased production
of oestrogen [81], and increased aromatase mRNA levels
were found in BC compared with normal breast tissue
[82]. Treatment of ER+ BC in postmenopausal womenImmunofluorescence staining of high mammographic density (HMD)
immune cell marker (c) are shown as well as the overlay of all stain
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portant role that aromatase plays in the extraovarian
oestrogen biosynthesis, and it is the treatment of choice
for postmenopausal ER+ tumours [83]. Forced expression
of aromatase in mouse mammary glands led to hyperpla-
sia and tumour growth, suggesting aromatase’s tumori-
genic potential when its expression becomes aberrant
[84]. In a recent study on the breast fat precursor cells
(referred to as human adipose stromal cells) isolated from
women who underwent reduction mammoplasty, re-
searchers found that high cell culture density and in-
creased ECM presence significantly induced aromatase
expression in vitro [85]. Additionally, Vachon and co-
workers found, in a group of 49 healthy women aged 40–
82 years, that aromatase immunoreactivity was signifi-
cantly higher in epithelial and stromal cells of dense re-
gions than in nondense tissues sampled using core
biopsies [86]. In keeping with their findings, we also ob-
served significantly increased levels of aromatase expres-
sion in both epithelial and stromal components of HMD
tissue compared with LMD. Increased aromatase expres-
sion in HMD regions (increased stroma and epithelium,
but less fat) may be reflective of a higher number of im-
mature stromal preadipocytes, which is a source of aroma-
tase activity [87, 88].
In the large International Breast Cancer Intervention
Study (IBIS) I prevention trial, investigators assessed the
effect of tamoxifen on MD in healthy women and dem-
onstrated a significant reduction of MD after 12–18
months of therapy [89]. This finding reflected MD as a
hormonally modulated phenotype, despite its lack of as-
sociation with ER+ or ER− BCs. On the basis of our re-
sults, aromatase expression, but not ER and/or PR
status, appears to correlate with HMD. To date, re-
searchers in several small studies (less than 100 women
with study period ranging from 6 to 24 months) have
published results of changes in MD in response to AIs.
These results are largely conflicting and affected by fac-
tors such as low baseline MD and patients previously re-
ceiving long-term tamoxifen before commencement of
AIs [47, 90, 91]. More recently, Henry et al. observed a
significant decrease in mean percentage MD (from 17.1 %
to 15.1 %) in 259 postmenopausal women with BC who
were initiating adjuvant AI therapy and randomly
assigned to treatment with exemestane (25 mg) or letro-
zole (2.5 mg) daily for 2 years [92]. In a case–control
study where 387 patients with postmenopausal BC were
treated with either anastrozole (1 mg daily) or exemes-
tane (25 mg daily), 10-month AI therapy was associated
with a 5 % or greater decrease in MD in 56 cases. How-
ever, this reduction was not significant compared with
their controls, which were matched for age, BMI and
baseline MD [42]. In the IBIS-II trial, investigators have
also found a 53 % risk reduction in women aged 40 to 70years who took 1 mg of oral anastrozole for 5 years (1920
cases and 1944 controls) for BC prevention [93]. How-
ever, MD has not yet been assessed in association with
the risk reduction.
High mammographic density tissue has lower abundance
of CD206+ alternatively activated macrophages
Macrophages in established tumours exert well-
described effects on angiogenesis, invasion, metastasis
and suppression of antitumour immunity [94, 95]. How-
ever, the relationship between macrophages and tumori-
genesis is complex, as macrophages are also involved in
immune surveillance that protects against tumorigenesis,
as well as in tumour-initiating roles such as production
of DNA-damaging agents, including reactive oxygen spe-
cies and reactive nitrogen intermediates. Macrophage
functions can be classified on the basis of how they are
activated. Classically activated (M1) macrophages are ac-
tivated by interferon γ (IFNγ) and microbial products,
whereas alternatively activated (M2) macrophages are
activated by interleukin (IL)-4, IL-10 and IL-13. M1
macrophages express high levels of proinflammatory
cytokines, are able to kill pathogens and can prime anti-
tumour responses, whereas M2 macrophages exhibit in-
creased expression of IL-10 anti-inflammatory cytokines.
The majority of tumour-associated macrophages are alter-
natively activated, as they promote tumour angiogenesis
and tissue remodelling and their major product, IL-10, has
known immunosuppressive roles [96, 97].
We found that the abundance of alternatively activated
CD206+ macrophages was significantly reduced in HMD
tissue compared with LMD tissue. Although the role of
macrophages in tumour initiation and the early stages of
tumorigenesis in BC is largely unknown, it is plausible that
in normal breast tissue the alternatively activated macro-
phages assist in dampening immune responses, thus redu-
cing the risk of inflammation-driven tumour initiation
[98]. Interestingly, macrophages have been identified as
key cells in the fibrillogenesis of collagen during
mammary gland development in mice [62], and they may
play a similar role in promoting increased organization of
collagen associated with HMD. Furthermore, Morris et al.
observed elevated aromatase expression as well as macro-
phages forming crown-like structures (CLSs) surrounding
necrotic adipocytes in the mammary glands of obese mice
as well as in tissue samples of 14 obese women [99] using
a CD68 antibody that also stains for other myeloid cells
and fibroblasts [100]. They postulated that the CLSs could
be a useful biomarker for increased BC risk. We did not
observe CLSs in the HMD and LMD samples after stain-
ing them with a CD68 antibody that we have found to be
specific for macrophages. This could also be due to the
fact our cohort was not specifically selected to include
obese women.
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increased vimentin+ immune cells in the epithelial layer
of high mammographic density tissue
We were able to demonstrate increased epithelial com-
partments in HMD compared with LMD in our study,
but we were also interested in determining whether the
increased MD correlated with a more immature epithe-
lial cell compartment. We assessed the proportion of
basal and luminal cells within the HMD tissue using
CK-14, CK-19 and vimentin triple IF staining and
showed that it was not significantly altered compared
with LMD. Vimentin was also included as a test for
evidence of EMT, which has been implicated in many
aspects of cancer progression and cancer initiation
[22, 101]. In particular, Raviraj and colleagues observed
EMT in solitary primary tumour cells in dense collagen
stroma, as these cells were positive for both vimentin
and CK-19 [102]. However, no such overt evidence of
EMT was seen in either LMD or HMD specimens in
our study. Vimentin staining was observed surrounding
the glandular tissue, where it stained both stromal fibro-
blasts and some of the basal myoepithelial cells, which
also costained with CK-14.
To our surprise, we noticed that there were aberrantly
positioned vimentin+ cells within the luminal compart-
ment of the epithelial cell layer that were negative for
CK-14 and CK-19, suggesting that they were not myoe-
pithelial cells or mature epithelial cells undergoing EMT.
To probe the identity of these cells, we costained with
vimentin and a pan-immune cell marker, CD45. The
vimentin+ cells in the epithelial layer that were not CK+
were positively identified as CD45+ immune cells. Fur-
ther analysis demonstrated that a subset of these cells
were also CD68+ macrophages (data not shown). This
suggests that the HMD samples have increased vimentin+
immune cells present within the epithelial layer, which
may lead to increased local inflammation.
Inflammation in cancer development bears the analogy
of a double-edged sword: on one hand, lymphocytes ac-
tively seek out and eradicate dysplastic cells to suppress
tumour formation; on the other hand, cancers have been
observed to arise from areas of chronic inflammation
[32, 103]. The important role of immunosurveillance in
cancer prevention has been demonstrated in immunode-
ficient mice such as IFNγ-deficient mice [104]. In
humans, patients with innately deficient immune sys-
tems or those who with immunosuppression due to
medical therapy, have an increased risk of developing
certain types of cancer, such as Hodgkin’s lymphoma
and Kaposi sarcoma [105]. Interestingly, where local in-
flammation remains chronic, such as in cases of inflam-
matory bowel disease or chronic Helicobacter pylori
infection of the stomach, the frequency of cancer is also
increased [106]. Traditionally, BCs are not viewed to beimmunogenic, as the incidence is not increased in pa-
tients with immunodeficiency [107]. However, Hussein
and colleagues [108] found that CD3+ T cells and CD20+
B cells were significantly increased in cancerous breast
tissue compared with benign breast tissue in 53 mastec-
tomy cases. Few studies have attempted to measure
whether the effect of inflammation on breast carcino-
genesis is mediated through independent effects on MD.
In a case–control study of 542 postmenopausal women,
Reeves et al. did not find any association of IL-6, tumour
necrosis factor-α or C-reactive protein with MD upon
adjustment for BMI [109]. Also, the Australian Mammo-
graphic Density Twins and Sisters Study researchers re-
ported no association between MD with the use of
aspirin and other nonsteroidal anti-inflammatory drug
(NSAID) use in 3286 women, based on multiple linear
regression analysis [110]. Nevertheless, using paired ana-
lysis of HMD and LMD samples, we observed that the
epithelium in HMD exhibited increased numbers of
vimentin+ immune cell infiltration, whereas the stromal
area in HMD had reduced numbers of alternatively acti-
vated macrophages, suggesting an altered balance between
anti- and proinflammatory signals in HMD epithelium
and stroma. Only a proportion of vimentin+/CD45+ cells
stained positive for macrophages using the pan-
macrophage marker CD68. CD45 is a pan-inflammatory
marker that stains positive for most cells of hematopoietic
origin, such as adaptive immune (T and B lymphocytes)
cells, as well as myeloid-derived suppressor cells. Our data
suggest that the abundance and phenotype of immune
system cells are altered in the microenvironment in HMD
tissue. Although we specifically investigated macrophages,
it is likely that other components are also affected by MD.
Further analysis of the identity of the CD45+/vimentin+
population that we have shown, as well as comparison of
T and B cell populations surrounding lobules and ducts in
HMD and LMD samples, may reveal further differences
in the immune microenvironment that affects BC risk, as
has been described previously [111].
Strengths and limitations
We acknowledge that MD of the breast is greatly influ-
enced by age, BMI, menopausal status and menstrual
cycle, and immune cell infiltration along with collagen
level could also vary with parity status [60, 112]. Al-
though our within-individual matched-pairs design elim-
inated such confounders from our comparison of HMD
and LMD tissue specimens from the same woman, we
may still see differences in the size and/or scope of
HMD/LMD differential effects, depending on parity and
parity-related issues. The sampling of non-neoplastic
breast tissue enabled us to examine features unique to
HMD specimens that may be responsible for increased
BC risk before tumorigenesis takes place. Our study
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opausal and parous women with an elevated BC risk
compared with the average population and thus may not
be fully representative of the general population. How-
ever, MD was not shown to bear any relationship with
BRCA1/2 carrier status versus BRCA1/2− but familial
high-risk women (approximately one-third of the cases
are not BRCA1/2 carriers) [12, 25]. BRCA1/2 status does
not affect MD [113], and MD confers an elevated risk in
BRCA1/2 carriers similar to that of sporadic women
[114]. Therefore, it is likely that the compositional and
cellular changes we observed in this study population
are translatable to the general population.Conclusions
This study confirms that HMD breast tissue is com-
posed of significantly greater proportions of epithelium,
stroma and collagen, and less adipose tissue, than LMD
regions of the same breast. This finding has been re-
ported in previously published studies. Consistent with
most published data, our findings were that there were
similar levels of ER, PR and Ki-67 expression, as well as
increased aromatase immunoreactivity, in HMD tissue.
To date, there is no evidence in the literature on the
relationship of MD with collagen architecture and orien-
tation, macrophage infiltration, subepithelial cell propor-
tions or the level of immune cell influx. To our
knowledge, the present study is the first to show that
HMD tissue has enhanced stromal collagen organisation,
significantly reduced stromal alternatively activated
macrophage infiltration and increased abundance of
vimentin+ immune cells within the epithelial compart-
ment. Increased BC risk associated with high MD is
likely a result of longitudinally cumulative exposure to
increased epithelium, dense stromal architecture and
various growth and hormonal factors in a breast micro-
environment that promotes mitosis, inflammation and
subsequent malignant transformation.Additional files
Additional file 1: MD semiquantitative assessment using the MD
tissue index. Upon reviewing H&E-stained slides, tissue samples were
assigned to one of the five categories: (1) 0 % to 10 % of tissue was
stroma and/or epithelium/tissue section (A); (2) 11 % to 25 % of tissue
was stroma and/or epithelium/tissue section (B); (3) 26 % to 50 % of
tissue was stroma and/or epithelium/tissue section (C); (4) 51 % to 75 %
of tissue was stroma and/or epithelium/tissue section (D); and (5) >75 %
of tissue was stroma and/or epithelium/tissue section (E). (F) Scatterplot
of assigned density category based on the percentage of stroma and
epithelium per specimen shows that this categorical method of assessing
MD produced results consistent with those derived from JMicroVision
analyses as shown in Fig. 3 (n = 41 women). HMD high mammographic
density, LMD low mammographic density. Owing to the different sizes of
whole tissue sections, we show entire tissues, hence the inconsistencies
of scales shown.Additional file 2: Assessment of histological composition for
parous and premenopausal women. (A) The distribution of participants
by their parity and menopausal status. (B) The quantitative analyses by
Wilcoxon matched-pairs signed-rank test of stroma, epithelium and fat
percentages in premenopausal women [subset a (n = 37) shown in (A)].
(C) Quantitative analyses of stroma, epithelium and fat percentages in
premenopausal women [subset b (n = 28) in (A)]. (D) Quantitative
analyses of stroma, epithelium and fat percentages in parous and
premenopausal women [subset d (n = 25) in (A)]. HMD high mammographic
density, LMD low mammographic density.
Additional file 3: Assessment of histological composition for
nulliparous and peri- or postmenopausal women. Quantitative
analyses by Wilcoxon matched-pairs signed rank test of the histological
compositions of nulliparous women (n = 4) (A), perimenopausal women
(n = 5) (B), postmenopausal women (n = 8) (C) and peri- and postmenopausal
women (n = 13) (D). HMD high mammographic density, LMD low
mammographic density.
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